George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
News|Articles|May 2, 2025
Nephrology Month in Review: April 2025
Author(s)Abigail Brooks, MA
Fact checked by: Victoria Johnson
The month in review spotlights renal FDA news and novel research about CKD and social determinants of health in kidney care.
Advertisement
Advertisement
The nephrology landscape saw meaningful developments in April, from US Food and Drug Administration action on glomerular diseases to studies highlighting ongoing challenges in
Related to this article
Pranav Garimella discusses what a potential USPSTF kidney screening recommendation could mean for high-risk adults and primary care.
As the USPSTF considers evidence for updated CKD screening guidance, Garimella discusses gaps in kidney disease detection and what the review should capture.
Ochsner Transplant Institute director discusses liver transplant care, robotic kidney transplant, organ preservation, and access gaps.
Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).
Approval covers patients aged ≥2 years with frequently relapsing or steroid dependent disease in complete remission.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
Advertisement
Advertisement